IGXT - IntelGenx Technologies Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
0.5500
-0.0050 (-0.90%)
At close: 2:19PM EDT
Stock chart is not supported by your current browser
Previous Close0.5550
Open0.5245
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.5027 - 0.5587
52 Week Range0.3900 - 1.8000
Volume69,414
Avg. Volume60,798
Market Cap51.44M
Beta (3Y Monthly)1.87
PE Ratio (TTM)N/A
EPS (TTM)-0.1230
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.25
Trade prices are not sourced from all markets
  • GlobeNewswire

    IntelGenx to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    IntelGenx Technologies Corp. (IGX.V)(IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that its CEO, Dr. Horst G. Zerbe, is scheduled to present at the H.C. Wainwright 21st Annual Global Investment Conference on Monday, September 9, 2019 at 1:45 p.m. ET at the Lotte New York Palace Hotel. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx's annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities at www.sedar.com.

  • IntelGenx (IGXT) Reports Q2 Loss, Misses Revenue Estimates
    Zacks

    IntelGenx (IGXT) Reports Q2 Loss, Misses Revenue Estimates

    IntelGenx (IGXT) delivered earnings and revenue surprises of -50.00% and -78.11%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    IntelGenx Reports Second Quarter 2019 Financial Results

    SAINT LAURENT, Quebec, Aug. 08, 2019 -- IntelGenx Technologies Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today reported.

  • GlobeNewswire

    IntelGenx to Report Second Quarter 2019 Financial Results on August 8, 2019 – Conference Call to Follow

    SAINT LAURENT, Quebec, Aug. 01, 2019 -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its.

  • Will IntelGenx (IGXT) Report Negative Q2 Earnings? What You Should Know
    Zacks

    Will IntelGenx (IGXT) Report Negative Q2 Earnings? What You Should Know

    IntelGenx (IGXT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    IntelGenx to Present at 12th Edition of Clinical Trials on Alzheimer’s Disease

    IntelGenx Corp. (IGX.V) (IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will present a Montelukast poster at the 12th edition of Clinical Trials on Alzheimer’s Disease (CTAD2019), to be held in San Diego, California, from December 4-7, 2019. The poster, entitled “The BUENA Study: A Phase 2a Clinical Trial to Test Safety and Efficacy of Montelukast VersaFilm®in Alzheimer’s Patients,” will be presented in collaboration with Prof. Dr. Ludwig Aigner’s group fromthe Paracelsus Medical University in Salzburg. “Our studies of Montelukast have garnered positive feedback from the Alzheimer’s disease community to-date, so we are looking forward to presenting our ongoing BUENA studyat CTAD2019,”said Dr. Horst G. Zerbe, CEO of IntelGenx.

  • GlobeNewswire

    IntelGenx Announces Addition of Peterborough’s Kawartha Centre as Montelukast VersaFilm® Phase 2a Clinical Trial Site

    IntelGenx Corp. (IGX.V) (IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that, the Kawartha Centre has agreed to participate in IntelGenx’s Montelukast VersaFilm® Phase 2a BUENA clinical trial in patients with mild to moderate Alzheimer’s Disease (“AD”). In addition, IntelGenx is honoured that renowned clinical researcher, Dr. Donald V. Doell, has agreed to serve as the site’s lead investigator. Based in Peterborough, Ontario, the Kawartha Centre’s corporate vision is to redefine healthy aging through expert, comprehensive, compassionate care for people facing memory loss, dementia and other related challenges.  In addition, Kawartha Centre’s vision is to improve the lives of patients, families, caregivers and communities from assessment and treatment to research and advocacy.

  • GlobeNewswire

    IntelGenx Announces Addition of Ottawa Montelukast VersaFilm® Phase 2a Clinical Trial Site; First Patient in Study Completes 26-Week Treatment

    IntelGenx Corp. (IGX.V) (IGXT) (“IntelGenx”), leader in pharmaceutical films, today announced that it has added a new Ottawa site in the Montelukast VersaFilm® Phase 2a (“BUENA”) clinical trial in patients with mild to moderate Alzheimer’s Disease (“AD”). BUENA is a randomized, double-blind, placebo-controlled Phase 2a “proof of concept” study designed to assess Montelukast VersaFilm® in approximately 70 patients with mild to moderate AD. BUENA will evaluate the safety, feasibility, tolerability, and efficacy of Montelukast buccal film following daily dosing for 26 weeks.

  • GlobeNewswire

    IntelGenx Receives First Shipment of Cannabis Extract from Tilray® for Production of Cannabis-Infused Oral Film

    IntelGenx Corp. (IGX.V) (IGXT) (“IntelGenx”), a leading oral drug delivery company, today provided an update on its cannabis-infused VersaFilm® product co-development program with Tilray, Inc. (TLRY) (“Tilray®”), a global leader in cannabis research, cultivation, production, and distribution. IntelGenx recently received the first shipment of cannabis extract from Tilray, providing it with sufficient quantities to commence batch production of cannabis-infused VersaFilm®. This supply of cannabis extract allows us to advance development and production of Cannabis-Infused VersaFilm® products, marking an important milestone for the co-development program.

  • GlobeNewswire

    IntelGenx to Join the Quebec Pavilion at BIO 2019 International Convention

    IntelGenx Corp. (IGX.V) (IGXT) (“IntelGenx”), leader in pharmaceutical films, today announced that it will be joining the Quebec Pavilion at Booth #2627 at BIO 2019 International Convention taking place on June 3-6, 2019 in Philadelphia, PA. IntelGenx will be promoting its contract development and manufacturing organization (“CDMO”) service capabilities utilizing its oral film and transdermal technologies. VersaFilm® and VetaFilm™ are IntelGenx’s proprietary oral drug delivery technology platforms for human and veterinary applications, respectively. They enable the development of oral films with potential to improve absorption, accelerate onset of action, reduce side effects, ease administration and improve patient compliance. Transdermal technology is the latest addition to IntelGenx’s drug delivery portfolio.

  • Associated Press

    IntelGenx: 1Q Earnings Snapshot

    On a per-share basis, the Ville Saint Laurent, Quebec-based company said it had a loss of 3 cents. The drug delivery technology company posted revenue of $416,000 in the period. In the final minutes of ...

  • GlobeNewswire

    IntelGenx Reports First Quarter 2019 Financial Results

    IntelGenx Technologies Corp. (IGX.V)(IGXT) (the "Company" or "IntelGenx") today reported financial results for the first quarter ended March 31, 2019. All dollar amounts are expressed in U.S. currency and results are reported in accordance with United States generally accepted accounting principles except where noted otherwise.

  • GlobeNewswire

    IntelGenx Announces the Appointment of André Godin as President and Chief Financial Officer

    In his newly expanded role, Mr. Godin will have overall responsibility for day-to-day operations, financial reporting and budgeting, as well as managing the Company's relationships and interactions with the investment community.  He will continue to report to the Company’s CEO, Dr. Horst G. Zerbe. “André’s contributions to IntelGenx have already been immeasurable and he is exceptionally well qualified to take on this expanded role. “I sincerely appreciate this additional vote of confidence from the Board,” commented Mr. Godin.

  • GlobeNewswire

    IntelGenx and Aquestive Therapeutics Enter Worldwide Collaboration Agreement for Tadalafil

    IntelGenx Corp. (IGX.V) (IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that it has entered into a definitive worldwide agreement with Aquestive Therapeutics, Inc. (AQST) (“Aquestive”), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, for the co-development and commercialization of Tadalafil oral films (the “Agreement”) for the treatment of erectile dysfunction (“ED”). The companies will jointly undertake further co-development and commercialization of Tadalafil oral film products, and will equally share (50/50) net profits from worldwide product sales.

  • GlobeNewswire

    IntelGenx to Report First Quarter 2019 Financial Results on May 9, 2019 – Conference Call to Follow

    SAINT LAURENT, Quebec, May 02, 2019 -- IntelGenx Technologies Corp. (TSX VENTURE:IGX) (OTCQX:IGXT) today announced that it will release its first quarter 2019 financial results.

  • GlobeNewswire

    IntelGenx Announces Issuance of Second U.S. Patent for Topical Oral Film Technology

    IntelGenx Corp. (IGX.V) (IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that the United States Patent and Trademark Office has issued U.S. Patent 10,272,038 entitled “Film Dosage Form with Extended Release Mucoadhesive Particles.” The patent covers the design and manufacturing of topical oral films (“TOF”) for the local (topical) treatment of diseases of the oral mucosa using mucoadhesive particles. This patent is in the same family as U.S. Patent 9,668,970 – issued to IntelGenx in June 2017 – and provides broader coverage for IntelGenx’s proprietary technology, which is intended to provide sustained release of an active agent to a target area of the oral cavity. The technology is useful for the topical treatment of oral diseases and conditions such as gingivitis, buccal ulcers, canker sores, Sjögren’s syndrome, oral mucositis and Behcet’s disease.

  • GlobeNewswire

    IntelGenx to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference

    IntelGenx Corp. (IGX.V) (IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that its Executive Vice-President and Chief Financial Officer, Andre Godin, is scheduled to present at the 2019 Bloom Burton & Co. Healthcare Investor Conference on April 30, 2019 at 2:30 p.m. ET at the Metro Toronto Convention Centre. Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm® and VetaFilm™ technology platforms. IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services.

  • GlobeNewswire

    IntelGenx to Promote Oral Films CDMO Services at CPhI North America

    SAINT LAURENT, Quebec, April 23, 2019 -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that it will promote its.

  • GlobeNewswire

    IntelGenx Files Non-Provisional U.S. Patent Application for Oil-Based Active Ingredients

    The patent application covers a newly-developed platform that enables the incorporation of oil-based (lipophilic) active ingredients into oral film formulations. The technology may also be used when more than one active ingredients, such as THC and CBD, are applied in a single film product. “This new filing adds to the global intellectual property estate that we are building for VersaFilmTM and VetaFilmTM,” said Dr. Horst G. Zerbe, President and CEO of IntelGenx.

  • GlobeNewswire

    IntelGenx to Promote VetaFilm™ Oral Film Technology at Human Biotech & Animal Health Business Partnering Summit

    IntelGenx Corp. (IGX.V) (IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that it will promote its proprietary VetaFilm™ oral film technology for companion animal drug delivery at the Human Biotech & Animal Health Business Partnering Summit taking place on April 9, 2019 in Boston, MA. VetaFilm™ technology is compatible with a wide variety of actives such as cannabinoids. “We are excited to be a part of the Human Biotech & Animal Health Business Partnering Summit,” said Horst G. Zerbe, President and CEO of IntelGenx.

  • GlobeNewswire

    IntelGenx Presents at 14th International Conference on Alzheimer’s and Parkinson’s Disease

    IntelGenx Corp. (IGX.V) (IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced its two Montelukast poster presentations received positive and constructive feedback from the Alzheimer’s Disease (AD) scientific community at the 14th International Conference on Alzheimer’s & Parkinson’s Diseases in Lisbon, Portugal. The poster presentations were presented in collaboration with Prof. Dr. Ludwig Aigner’s group at the Paracelsus Medical University in Salzburg. The first poster entitled “The Leukotriene Receptor Antagonist Montelukast Improves Cognitive Function in the 5xFAD Model of Alzheimer’s Disease” presented a preclinical study of Montelukast in an AD mouse model, whereby 45 five-month old mice were treated with either Montelukast or placebo via an adhesive buccal film for 13 weeks.

  • GlobeNewswire

    IntelGenx Receives Complete Response Letter from FDA for RIZAPORT® NDA

    The Agency requested additional information, but no new bioequivalence study. "We believe the recommendations stated in the CRL are manageable and we remain committed to working closely with the FDA to make this innovative new oral film product available to people suffering from migraines,” said Horst G. Zerbe, President and CEO of IntelGenx. IntelGenx continues to look forward to working with its partner, Gensco® Pharma, to commercialize RIZAPORT® in the United States upon FDA approval.

  • GlobeNewswire

    IntelGenx Grants Stock Options

    SAINT LAURENT, Quebec, March 27, 2019 -- IntelGenx Technologies Corp. ("IntelGenx", or the “Company”) (TSX-V: IGX) (OTC.QX:IGXT) announced today that the Company’s board of.

  • GlobeNewswire

    IntelGenx Reports Fourth Quarter and Full-Year 2018 Financial Results

    SAINT LAURENT, Quebec, March 22, 2019 -- IntelGenx Technologies Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx") today reported financial results for the fourth.

  • GlobeNewswire

    IntelGenx to Report Fourth Quarter and Full-Year 2018 Financial Results on March 25, 2019 – Conference Call to Follow

    SAINT LAURENT, Quebec, March 18, 2019 -- IntelGenx Technologies Corp. (TSX VENTURE:IGX)(OTCQX:IGXT) today announced that it will release its fourth quarter and full year 2018.